Patrick Garnero

Summary

Country: France

Publications

  1. doi request reprint Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of th
    Patrick Garnero
    INSERM Unit 664, Lyon, France
    Arthritis Rheum 62:33-43. 2010
  2. doi request reprint Development of a new ELISA for serum periostin: evaluation of growth-related changes and bisphosphonate treatment in mice
    Sylvain Contie
    Institut National de la Sante et de la Recherche Medicale, Lyon, France
    Calcif Tissue Int 87:341-50. 2010
  3. doi request reprint Increased cartilage type II collagen degradation in patients with osteogenesis imperfecta used as a human model of bone type I collagen alterations
    Jean Charles Rousseau
    INSERM Research Unit 831, Universite de Lyon, Lyon, France
    Bone 46:897-900. 2010
  4. ncbi request reprint Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study
    Patrick Garnero
    INSERM Research Unit 403, Hopital E Herriot, Lyon, France
    J Bone Miner Res 18:1789-94. 2003
  5. ncbi request reprint Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept
    Patrick Garnero
    INSERM Research Unit 664, Lyon, France
    J Rheumatol 35:2313-5. 2008
  6. doi request reprint Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations
    Patrick Garnero
    INSERM Research Unit 664, Lyon, France
    Bone 44:461-6. 2009
  7. pmc Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study
    Patrick Garnero
    INSERM Research Unit 664, Lyon, France
    J Bone Miner Res 23:1442-8. 2008
  8. ncbi request reprint Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study
    Patrick Garnero
    INSERM Research Unit 403, and Synarc, Lyon, France
    Arthritis Rheum 46:2847-56. 2002
  9. ncbi request reprint Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis
    Nadine Charni
    Synarc, Lyon, France
    Arthritis Rheum 52:1081-90. 2005
  10. doi request reprint Assessment of circulating Dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastases
    Nathalie Voorzanger-Rousselot
    Biochemical Markers, Synarc, Lyon, France
    Calcif Tissue Int 84:348-54. 2009

Detail Information

Publications26

  1. doi request reprint Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of th
    Patrick Garnero
    INSERM Unit 664, Lyon, France
    Arthritis Rheum 62:33-43. 2010
    ....
  2. doi request reprint Development of a new ELISA for serum periostin: evaluation of growth-related changes and bisphosphonate treatment in mice
    Sylvain Contie
    Institut National de la Sante et de la Recherche Medicale, Lyon, France
    Calcif Tissue Int 87:341-50. 2010
    ..The novel ELISA is highly specific and allows accurate and precise measurements of serum periostin levels in mice...
  3. doi request reprint Increased cartilage type II collagen degradation in patients with osteogenesis imperfecta used as a human model of bone type I collagen alterations
    Jean Charles Rousseau
    INSERM Research Unit 831, Universite de Lyon, Lyon, France
    Bone 46:897-900. 2010
    ..We investigated whether cartilage degradation is altered in adult patients with mild osteogenesis imperfecta (OI) used as a human model of bone type I collagen-related osteoarthritis (OA)...
  4. ncbi request reprint Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study
    Patrick Garnero
    INSERM Research Unit 403, Hopital E Herriot, Lyon, France
    J Bone Miner Res 18:1789-94. 2003
    ..Seventy percent to 80% of women classified as having high bone turnover at baseline were similarly classified by the same methods 4 years later...
  5. ncbi request reprint Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept
    Patrick Garnero
    INSERM Research Unit 664, Lyon, France
    J Rheumatol 35:2313-5. 2008
    ..Dickkopf-1 (Dkk-1) regulates bone remodeling in animal models of inflammatory arthritis, but its role in patients with rheumatoid arthritis (RA) remains unclear...
  6. doi request reprint Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations
    Patrick Garnero
    INSERM Research Unit 664, Lyon, France
    Bone 44:461-6. 2009
    ..Urinary alpha/betaCTX ratio has been proposed to reflect collagen maturation. We investigated changes in bone turnover and Col I isomerization in adult patients with OI and their relationship with Col I gene mutations...
  7. pmc Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study
    Patrick Garnero
    INSERM Research Unit 664, Lyon, France
    J Bone Miner Res 23:1442-8. 2008
    ..The influence of these biochemical changes of type I collagen on bone fracture resistance remains to be studied...
  8. ncbi request reprint Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study
    Patrick Garnero
    INSERM Research Unit 403, and Synarc, Lyon, France
    Arthritis Rheum 46:2847-56. 2002
    ....
  9. ncbi request reprint Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis
    Nadine Charni
    Synarc, Lyon, France
    Arthritis Rheum 52:1081-90. 2005
    ..The aim of this study was to develop a biochemical marker reflecting the degradation of the helical region of type II collagen and to evaluate its clinical performance in patients with osteoarthritis (OA) and rheumatoid arthritis (RA)...
  10. doi request reprint Assessment of circulating Dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastases
    Nathalie Voorzanger-Rousselot
    Biochemical Markers, Synarc, Lyon, France
    Calcif Tissue Int 84:348-54. 2009
    ..Measurements of circulating Dkk-1 with this new ELISA may be useful for the clinical investigation of patients with malignant bone diseases...
  11. ncbi request reprint Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring
    Patrick Garnero
    INSERM Unit 664, Laennec School of Medicine, Lyon, France
    Mol Diagn Ther 12:157-70. 2008
    ..Thus, repeated measurements of bone markers during therapy may help improve the management of osteoporosis in patients...
  12. ncbi request reprint Cross-sectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: the ECHODIAH cohort
    Patrick Garnero
    INSERM Unit 403 and Molecular Markers, Synarc, Lyon, France
    J Rheumatol 32:697-703. 2005
    ..To investigate the associations of molecular markers of joint tissue turnover with clinical and radiological variables in patients with hip osteoarthritis (OA)...
  13. ncbi request reprint Association between spine disc degeneration and type II collagen degradation in postmenopausal women: the OFELY study
    Patrick Garnero
    INSERM Research Unit 403, Synarc, Lyon, France
    Arthritis Rheum 50:3137-44. 2004
    ....
  14. ncbi request reprint Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: bone biomarkers
    Patrick Garnero
    INSERM Research Unit 403, Lyon, France
    Curr Opin Rheumatol 16:428-34. 2004
    ..More specific biologic markers reflecting systemic quantitative and dynamic changes of bone turnover represent promising adjunctive tools...
  15. ncbi request reprint Development and clinical application in arthritis of a new immunoassay for serum type IIA procollagen NH2 propeptide
    Jean Charles Rousseau
    INSERM Unit 403, Hopital E Herriot, Lyon, France
    Methods Mol Med 101:25-37. 2004
    ..0001) and 35% (p < 0.001), respectively, suggesting that type IIA collagen synthesis is altered in these arthritic diseases. The measurement of serum PIIANP may be useful for the clinical investigation of patients with joint diseases...
  16. ncbi request reprint Biomarkers in osteoarthritis
    Patrick Garnero
    INSERM Research Unit 403, Lyon, France
    Curr Opin Rheumatol 15:641-6. 2003
    ..Biologic markers reflecting quantitative and dynamic changes of joint tissue turnover represent promising adjunct tools...
  17. ncbi request reprint Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study
    Patrick Garnero
    INSERM Unit 403, Hĵpital E Herriot, Lyon, France
    J Bone Miner Res 17:826-33. 2002
    ..This suggests that alterations of type I collagen isomerization/racemization that can be detected by changes in urinary CTX ratios may be associated with increased skeletal fragility...
  18. doi request reprint New automated multiplex assay for bone turnover markers in osteoporosis
    Aurélie Claudon
    CCBR SYNARC, Biochemical Markers, Lyon, France
    Clin Chem 54:1554-63. 2008
    ..We evaluated the performance characteristics of a novel, fully automated, protein-array chip system that allows the simultaneous measurement of CTX-I, PINP, OC, and intact parathyroid hormone (PTH) in 20 microL of serum...
  19. doi request reprint Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases
    Sylvain Contie
    Research Unit 664, Institut National de la Sante et de la Recherche Medicale, Lyon, France
    Int J Cancer 128:352-60. 2011
    ..Bone metastases from breast cancer induce overexpression of periostin by surrounding stromal cells. Periostin could be a biochemical marker of the early stromal response associated to breast cancer bone metastasis formation...
  20. ncbi request reprint Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis
    Patrick Garnero
    Synarc and Inserm Research Unit, Lyon, France
    Arthritis Rheum 46:21-30. 2002
    ....
  21. ncbi request reprint Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis
    Patrick Garnero
    INSERM Unit 664, Synarc Lyon, 16 rue Montbrillant, Lyon, France
    Clin Chem 54:188-96. 2008
    ..We evaluated the performance of a fully automated assay for serum total N-terminal propeptide of type I collagen (P1NP), a marker of bone formation...
  22. ncbi request reprint Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation
    Ulrich Valcourt
    INSERM Research Unit 403 and Université Lyon 1, Lyon, France
    J Biol Chem 282:5691-703. 2007
    ..We suggest that AGEs may play a role in the alterations of bone remodeling associated with aging and diabetes...
  23. ncbi request reprint Short-term effects of new synthetic conjugated estrogens on biochemical markers of bone turnover
    Patrick Garnero
    INSERM Research Unit 403, Hĵpital E Herriot, Lyon, France
    J Clin Pharmacol 42:290-6. 2002
    ..Synthetic conjugated estrogens significantly decreased bone resorption and bone formation comparable to that previously reported for estrogen treatments proven efficacious in preventing postmenopausal bone loss...
  24. doi request reprint Periostin and transforming growth factor β-induced protein (TGFβIp) are both expressed by osteoblasts and osteoclasts
    Blandine Merle
    INSERM Research Unit 1033, Universite Lyon 1, Lyon, France
    Cell Biol Int 38:398-404. 2014
    ..A novel finding is that Postn and TGFβIp are expressed by osteoclasts in vitro. Therefore Postn and TGFβIp proteins are potential biomarkers of early osteoblast differentiation and new bone formation...
  25. ncbi request reprint Biochemical markers in osteoarthritis: will they measure up?
    Patrick Garnero
    INSERM and Synarc Molecular Markers, Molecular Marker Division, Lyon, France
    Nat Clin Pract Rheumatol 2:116-7. 2006
  26. ncbi request reprint Effects of tibolone and combined 17beta-estradiol and norethisterone acetate on serum C-reactive protein in healthy post-menopausal women: a randomized trial
    Patrick Garnero
    INSERM Research Unit 403 and Synarc, Lyon, France
    Hum Reprod 17:2748-53. 2002
    ....